Latest News and Press Releases

Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "Bladder Cancer Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering.The...

Potential first-in-class, and industry-leading DNA polymerase Theta (Polθ) inhibitor, ART6043 demonstrated an attractive tolerability profile, expected PK/PD activity, and promising clinical...

Ingelheim, Germany / Ridgefield, Connecticut, U.S. Data from the Phase Ib Beamion LUNG-1 trial evaluating zongertinib in treatment-naïve patients with advanced HER2 (ERBB2)-mutant NSCLC were...

CAMBRIDGE, United Kingdom and NEW YORK, October 13, 2025 – Artios Pharma Limited (“Artios”), a biopharmaceutical company committed to realizing the therapeutic power of targeting the DNA damage...

NJ-founded MetasTx is advancing an NCI-backed diagnostic and next-gen KIT inhibitor for high-risk prostate cancer, aiming for 2026 validation.

U.S. Fast Track designation underscores the strength of the alnodesertib clinical data generated to date and the high degree of unmet need in 3L mCRC CAMBRIDGE, United Kingdom and NEW YORK, September...

OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a...

UTR Therapeutics Inc Publishes Data supporting US FDA IND for a First-in-Human Clinical Trial of mRNA destabilizing drug targeting c-MYC driven cancer

Philadelphia, PA, Sept. 04, 2025 (GLOBE NEWSWIRE) -- The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, announces the appointment of...

Mike Andriole brings approximately 25 years of experience in the biopharmaceutical industry and a successful track record of delivering new first-in-class oncology therapies in indications of high...